2023-08-03 09:07:09 ET
- ImmunityBio Inc ( NASDAQ: IBRX ) on Thursday named Enrique Diloné to the newly created role of Chief Technology Officer.
- Diloné will assume responsibility for all global manufacturing functions as the company prepares for potential FDA approval of a key bladder cancer drug.
- Prior to joining ImmunityBio, Diloné served as CTO of Prothelia, a privately held biotech company developing treatments for patients with congenital muscular dystrophy.
- Source: Press Release
For further details see:
ImmunityBio names Enrique Diloné as Chief Technology Officer